CTSO primary value is locked up in blood thinner removal. We need FDA pathway to US approval to unlock this value. I believe Chan when he says CTSO has limited ability to market for this application due to COVID. I believe COVID going away will be a big net positive. CTSO clearly is not putting much emphasis on Leveraging the EUA so wont be a big hit when it goes away.